OBJECTIVE: To determine the association of hypertension (HTN) and its treatment with sexual function in middle-aged and older adults. METHODS: We studied a nationally representative sample of community-residing adults aged 57-85 years (n = 3005) from the National Social Health, Life and Aging Project. Adults were categorized by HTN status (treated, untreated, and no HTN). Antihypertensive medication use was classified into calcium channel blocker; β-blocker; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; diuretic; and α-blocker. For each HTN and medication group, we determined the prevalence and adjusted odds of being sexually active and of having any sexual problem. RESULTS: Among men, comparing treated HTN with untreated HTN and no HTN, sexual activity was less prevalent (66.5 vs. 75.9 vs.71.5%, P <0.01) and sexual problems were more prevalent (69.1 vs. 57.7 vs. 54.3%; P ≤ 0.01). There was no association between treated HTN and sexual activity [odds ratio, OR = 0.86 (95% confidence interval 0.51-1.45)] and a nonsignificant association between treated HTN and sexual problems [OR = 1.49 (0.94-2.37)]. Among women, the prevalence of sexual activity was lower in the treated and untreated HTN groups than the no HTN group (35.2 vs. 38.3 vs. 58.0%, P <0.01); the prevalence of sexual problems was similar (73.7 vs. 65.3 vs. 71.7%; P = 0.301). Women in the treated HTN [OR = 0.61 (0.39-0.95)] and untreated HTN [0.54 (0.30-0.96)] groups had a lower odds of sexual activity compared with no HTN. There were no significant associations between antihypertensive medication class and sexual activity or problems in men or women. CONCLUSION: The relationship between HTN and sexual health is different for older men and women. Prospective, comparative effectiveness trials are needed.
OBJECTIVE: To determine the association of hypertension (HTN) and its treatment with sexual function in middle-aged and older adults. METHODS: We studied a nationally representative sample of community-residing adults aged 57-85 years (n = 3005) from the National Social Health, Life and Aging Project. Adults were categorized by HTN status (treated, untreated, and no HTN). Antihypertensive medication use was classified into calcium channel blocker; β-blocker; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; diuretic; and α-blocker. For each HTN and medication group, we determined the prevalence and adjusted odds of being sexually active and of having any sexual problem. RESULTS: Among men, comparing treated HTN with untreated HTN and no HTN, sexual activity was less prevalent (66.5 vs. 75.9 vs.71.5%, P <0.01) and sexual problems were more prevalent (69.1 vs. 57.7 vs. 54.3%; P ≤ 0.01). There was no association between treated HTN and sexual activity [odds ratio, OR = 0.86 (95% confidence interval 0.51-1.45)] and a nonsignificant association between treated HTN and sexual problems [OR = 1.49 (0.94-2.37)]. Among women, the prevalence of sexual activity was lower in the treated and untreated HTN groups than the no HTN group (35.2 vs. 38.3 vs. 58.0%, P <0.01); the prevalence of sexual problems was similar (73.7 vs. 65.3 vs. 71.7%; P = 0.301). Women in the treated HTN [OR = 0.61 (0.39-0.95)] and untreated HTN [0.54 (0.30-0.96)] groups had a lower odds of sexual activity compared with no HTN. There were no significant associations between antihypertensive medication class and sexual activity or problems in men or women. CONCLUSION: The relationship between HTN and sexual health is different for older men and women. Prospective, comparative effectiveness trials are needed.
Authors: Zoë Hyde; Leon Flicker; Graeme J Hankey; Osvaldo P Almeida; Kieran A McCaul; S A Paul Chubb; Bu B Yeap Journal: Ann Intern Med Date: 2010-12-07 Impact factor: 25.391
Authors: Dennis T Ko; Patricia R Hebert; Christopher S Coffey; Artyom Sedrakyan; Jeptha P Curtis; Harlan M Krumholz Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Stacy Tessler Lindau; Emily M Abramsohn; Shirley R Baron; Judith Florendo; Hope K Haefner; Anuja Jhingran; Vanessa Kennedy; Mukta K Krane; David M Kushner; Jennifer McComb; Diane F Merritt; Julie E Park; Amy Siston; Margaret Straub; Lauren Streicher Journal: CA Cancer J Clin Date: 2016-01-19 Impact factor: 508.702
Authors: Capri G Foy; Jill C Newman; Dan R Berlowitz; Laurie P Russell; Paul L Kimmel; Virginia G Wadley; Holly N Thomas; Alan J Lerner; William T Riley Journal: J Sex Med Date: 2019-01-14 Impact factor: 3.802
Authors: Capri G Foy; Jill C Newman; Dan R Berlowitz; Laurie P Russell; Paul L Kimmel; Virginia G Wadley; Holly N Thomas; Alan J Lerner; William T Riley Journal: J Sex Med Date: 2016-09 Impact factor: 3.802
Authors: Donald M Lamkin; Ha Yeon Sung; Gyu Sik Yang; John M David; Jeffrey C Y Ma; Steve W Cole; Erica K Sloan Journal: Psychoneuroendocrinology Date: 2014-10-12 Impact factor: 4.905
Authors: Holly N Thomas; Gregory W Evans; Dan R Berlowitz; Glenn M Chertow; Molly B Conroy; Capri G Foy; Stephen P Glasser; Cora E Lewis; William T Riley; Laurie Russell; Olubunmi Williams; Rachel Hess Journal: J Hypertens Date: 2016-06 Impact factor: 4.844